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36 Vaginal candidiasis is considered a frequent opportunistic mucosal infection and the second 
37 most common cause of vaginitis after bacterial vaginosis. In this work, different vaginal films 
38 based on chitosan, hydroxypropyl methylcellulose and blends of these polymers containing 
39 tioconazole, were developed and thoroughly characterized to improve the conventional 
40 therapeutics of vaginal candidiasis. Mechanical properties, swelling, adhesiveness, 
41 morphology, antifungal activity, hemocompatibility and cytotoxicity were evaluated. The 
42 drug solid state in the films was analyzed by thermal and X-ray diffraction analysis. Films 
43 showed homogeneous surfaces and presented similar mechanical properties and adhesiveness. 
44 Time-kill studies displayed that films were more active than both tioconazole pure drug and 
45 traditional tioconazole ovule against Candida albicans, which is probably related to the fact 
46 that tioconazole is in amorphous state inside the films. Although all formulations proved to be 
47 hemocompatible, films based only on chitosan exhibited a certain degree of cytotoxicity and 
48 therefore they should be avoided. The system based on chitosan-hydroxypropyl 
49 methylcellulose with 40% PEG 400 as plasticizer presented fast antimicrobial activity as well 
50 as the lowest swelling. Additionally, this formulation did not produce substantial hemolytic 
51 and cytotoxic effects, indicating that films based on chitosan-hydroxypropyl methylcellulose 

















67 Vaginal candidiasis is considered a frequent opportunistic mucosal infection in women, 
68 being the second most common cause of vaginitis after bacterial vaginosis (Egan and Lipsky, 
69 2000).  The disease affects 70 - 75% women at least once in their lifetime and around 50% of 
70 patients experience a recurrence (Costa-de-Oliveira et al., 2008). Although different Candida 
71 species may produce this disease, Candida albicans is the most prevalent yeast causing this 
72 infection. Vaginal candidiasis is commonly treated using azole antifungals, such as 
73 fluconazole, miconazole, itraconazole, clotrimazole, econazole, ketoconazole and tioconazole 
74 (Bassi and Kaur, 2015). Tioconazole (TCZ, (1[2-(2-chloro-3-thienyl) methoxy-2-(2,4-
75 dichlorro-phenyl)ethyl]-H-imidazole) is an imidazole antifungal agent with a broad spectrum 
76 of activity against a variety of microorganisms (Carrillo-Muñoz et al., 2010). This drug has 
77 been shown to hold higher activity against C. albicans than clotrimazole, econazole, 
78 ketoconazole and miconazole (Lefler and Stevens, 1984). This could be due to the fact that 
79 TCZ possesses antifungal activity even when yeast cells are in the stationary phase, while 
80 common antifungal agents such as ketoconazole and micronazole display with antimicrobial 
81 activity only when yeasts are in the growth phase (Beggs, 1984). 
82 The effectiveness of a treatment is not only determined by the antifungal compound 
83 type, but also by the development of an adequate dosage form, which is determinant in the 
84 biological activity of a therapeutic system. Particularly, pharmaceutical dosage forms for local 
85 vaginal delivery need to remain in the site of infection as long as possible and to be able to 
86 release the active compound according to the treatment. The use of conventional vaginal 
87 formulations such as creams, gels, pessaries, and foams is discouraged due to their poor 
88 retention in the vaginal tract by the tract’s self-cleansing action (Alam et al., 2007). Other 
89 conventional formulations such as vaginal tablets and ovules show good retention abilities, 
90 but both are rigid and may produce discomfort. Alternative bioadhesive vaginal formulations 
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91 such as films are suitable forms to achieve effective drug release for extended periods of time 
92 (Cautela et al., 2018; Ghosal et al., 2014; Machado et al., 2016; Mishra et al., 2017; 
93 Srinivasan et al., 2016; Traore et al., 2018; Yoo et al., 2009). In addition, these films present 
94 more flexibility than tablets and ovules, which may improve patients' compliance. 
95 Several biocompatible polymers such as chitosan (CH) and hydroxypropyl methyl 
96 cellulose (HPMC) have been employed to develop mucoadhesive films. CH, a cationic natural 
97 polymer widely used in pharmaceutical applications shows attractive biological properties 
98 including biocompatibility, biodegradability, non-toxicity, and physiological inertness 
99 (Krajewska, 2004). HPMC, a non ionic polymer, is a semi-synthetic cellulose derivative 
100 usually employed in the pharmaceutical industry, mainly as gelling agent and to control the 
101 release of pharmaceutical drugs (Kamel et al., 2008; Saha and Bhattacharya, 2010). 
102 The aim of this work was to develop and thoroughly characterize novel TCZ film 
103 dosage forms in order to improve the therapeutics of vaginal candidiasis. TCZ films were 
104 compared with the TCZ ovule, which is the traditional dosage form selected to treat the 
105 infectious disease. 
106  
107 2.  Materials and Methods
108 2.1. Chemicals
109 TCZ raw material of pharmaceutical grade (BP 2002) and PEG 400 were acquired in 
110 Saporiti (Buenos Aires, Argentina). During the experiments, the drug was kept in a desiccator. 
111 Double-distilled water was used for the preparation of aqueous solutions. TCZ vaginal ovule 
112 (“Honguil” from Raymos laboratories) containing 0.30 g TCZ and excipients [liquid vaseline 
113 (0.45 g) and solid vaseline (1.35 g)] was acquired in a local Drugstore (Rosario, Argentina). 
114 CH (230 KDa average molecular weight and 80.6% of N-deacetylation) was supplied by 
115 Aldrich Chemical Co. (Milwaukee, WI, USA). HPMC (MW 250 kDa, methoxyl content 19-
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116 24%, hydroxypropyl content 7-12%) was purchased from Eigenman & Veronelli (Milan, 




121 Films were prepared by solvent evaporation. CH solution (1% w/v) was obtained 
122 dispersing CH in 1% v/v lactic acid (v/v). TCZ was suspended in PEG 400 used as plasticizer 
123 and added to the CH solution. Aqueous solution of HPMC (1% w/v) was prepared and stirred 
124 overnight. Then, CH solution was dripped over HPMC solution at 40 °C to avoid precipitation 
125 and stirred at 200 rpm (Boecco stirrer, Germany) for 1 h. Finally, the solutions were cast on 
126 10 cm diameter Petri dishes and dried at 40 ºC. Unloaded films were developed following the 
127 same procedure but without adding TCZ to the mixtures, B1 consisted of 0.25:0.75 
128 (CH:HPMC) ratio and B2 1:0 (CH:HPMC) ratio. Dried films were removed from the Petri 
129 dishes and conditioned in a chamber at 25 °C and 80% RH for 24 h. 
130
131 Table 1. Composition of loaded films.
Film CH  1% w/v HPMC 1% w/v PEG (% w/w) TCZ (% w/w)
S1 0.25 0.75 5 15
S2 1 - 5 15
S3 0.25 0.75 40 15
S4 1 - 40 15
132
133 2.2.2.  Film Characterization
134 2.2.2.1. Thickness (TH) and folding endurance (FE)
135 For each system, six thickness measurements were made (around and in the center of 
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136 the films) with a digital micrometer (Schwyz, China). Folding endurance was determined by 
137 repeatedly folding the films at the same place until they broke or were folded 300 times 
138 (meeting the assay) (Avachat et al., 2013).
139
140 2.2.2.2. Mechanical properties: Load at break (LB) and Elongation at Break (EB)
141 The mechanical strength of the films was evaluated by using an Instron universal testing 
142 machine, EMIC 2350 (Instron, Norwood, MA, USA) with a 50 N load cell. Films for each 
143 mechanical test were conditioned (at 25 °C and 75% RH for 24 h) and cut into strips (7 mm 
144 wide and 60 mm long) to evaluate tensile properties. The initial grip distance was 30 mm and 
145 the crosshead speed was 5.0 mm/min. The parameters obtained from stress/strain curves were 
146 load at break (maximum force at breaking), and elongation (calculated as the percentile of the 
147 change in the length of film with respect to the original distance between the grips). For each 
148 mechanical probe, three replicate measurements were performed.
149
150 2.2.2.3. In vitro mucoadhesive strength (MS) 
151 An Instron universal testing machine, EMIC 2350 (Instron, Norwood, MA, USA) with a 
152 50 N load cell was employed to analyze the mucoadhesive strength of each film. The force 
153 required to detach each formulation from a disc of porcine vaginal mucosa (obtained from 
154 “Paladini” slaughterhouse, V.G. Galvez, Argentina) was measured. A portion of each film 
155 (2.5 cm diameter) was added to the upper end of the cylindrical probe and gum discs 
156 (obtained by punch biopsy and hydrated with 0.5 mL artificial vaginal fluid for 2 min) were 
157 horizontally attached to the lower end of the cylindrical probe by using double-sided adhesive 
158 tape (Tejada et al., 2018b). Simulated vaginal fluid pH value 4.2 (composed by (g L-1): NaCl, 
159 3.51; KOH, 1.40; Ca(OH)2, 0.222; bovine serum albumin, 0.018; lactic acid, 2.00; acetic acid, 
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160 1.00; glycerol, 0.160; urea, 0.400 and glucose, 5.00) was prepared according to previous 
161 literature (Owen and Katz, 1999). 
162  Each film remained in contact with the gum for 1 min and it was then moved upwards 
163 at a constant speed (1.0 mm/min). The test was carried out in triplicate. The force required to 
164 detach each film from the gum disc was determined from the resulting force/time plot.
165
166 2.2.2.4. Swelling index (SI)
167 Swelling measurements were determined by immersing an accurately weighted portion 
168 of the films (around 50 mg) in 0.5 mL simulated vaginal fluid at 37 ºC. 
169 Films were carefully removed at predetermined time intervals (0, 5, 10, 15, 20, 30, 45, 
170 60, 90, 120, 150, 180, 210, and 240 min), and the excess adhering moisture was gently blotted 
171 off, and weighed. Then, 0.5 mL of simulated vaginal fluid was added again. The swelling 
172 index was calculated using the weights of dried (Wo) and swollen (Ws) films (Eq. (1)). The 
173 test was carried out in triplicate.
174
175  6 (Eq. 1)
177
178
179 2.2.2.5. Fourier transformed infrared spectroscopy (FTIR)
180 Infrared (IR) spectra were acquired in a Shimadzu Prestige 21 spectrometer (Shimadzu 
181 Corp., Kyoto, Japan) over a wave number range of 4000-600 cm−1. ATR (attenuated total 
182 reflectance) experiments were carried out with a diamond-based ATR accessory (GladiATR, 
183 Pike Technologies, Madison, USA) fitted with a Pike temperature control unit. An average of 
184 20 scans was used at a 4 cm-1 resolution between 4000 and 600 cm-1 in all cases. The 





186 measurement were standardized. Each system was scanned three times and the measurements 
187 averaged.
188
189 2.2.2.6. Thermal analysis
190 Calorimetric determinations were performed in a Linseis PT1000 differential scanning 
191 calorimeter (DSC, Linseis Inc., New Jersey, USA), operating under a constant nitrogen flow 
192 (8 mL/min). Each sample, 2 mg (TCZ) or 5-6 mg (ovule and films), was placed in closed 
193 aluminum pans perforated with a pin-hole to equilibrate pressure from the potential expansion 
194 of evolved gases or residual solvents, and heated from 40 to 145 ºC at 10 ºC/min. An empty 
195 pan was used as a reference.
196 Thermogravimetric analysis (TGA) tests were carried out using a thermal analyzer 
197 (Model TGA Q500, Hüllhorst, Germany). Samples (around 8 mg) were heated at a constant 
198 rate of 10 °C/min from room temperature up to 600 °C under a nitrogen flow of 30 mL/min in 
199 order to avoid thermo oxidative reactions. 
200
201 2.2.2.7. X-ray diffraction analysis (XRD)
202 X-ray diffractograms were obtained with a PAN analytical X’Pert PRO diffractometer 
203 (Netherlands) equipped with a monochromatic CuKα radiation source (λ = 1.5406 Å) 
204 operating at a voltage of 40 kV and current 40 mA at a scanning rate of 0.02 º per sec. The 
205 scanning region was in a 2θ range from 5 ° to 40 °.
206  
207 2.2.2.8. Scanning electron microscopy (SEM)
208 The morphology of films was investigated by scanning electron microscopy (SEM, 
209 AMR 1000, Leitz, Wetzlar, Germany). Samples were mounted on an aluminum support using 
210 conductive, double-sided adhesive tape, and coated with a fine gold layer for 15 min at 70–80 
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211 mTorr in order to make them conductive before obtaining the SEM micrographs. All samples 
212 were examined using an accelerating voltage of 20 kV and magnifications of 200x, 1000x and 
213 5000x (Priotti et al., 2017).
214
215 2.2.2.9. Dissolution Studies
216 Dissolution studies were performed in 900 mL of distilled water (pH 4.3 mimic to the 
217 vaginal tract) at 37°C, using a USP XXIV Apparatus 2 (Paddle Apparatus) (Hanson Research, 
218 SR8 8-Flask Bath, Ontario, Canada) with paddles rotating at 50 rpm (Pharmacopoeia, 2017; 
219 Tejada et al., 2018b). TCZ raw material (135 mg) was dispersed in the dissolution medium. 
220 Films (containing 135 mg TCZ) were fixed to the central shaft using cyanoacrylate adhesive 
221 (Pharmacopoeia, 2017; Shaker et al., 2018; Tejada et al., 2017b). At different time intervals: 
222 0, 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 min, aliquot of 5 mL each were taken (without 
223 replacement) using a 0.45 μm filter. The amount of dissolved TCZ was determined by 
224 spectroscopic measures at 225 nm using an Agilent 8453 UV–DAD spectrophotometer 
225 (Agilent Technologies, Santa Clara, USA). Determinations were performed in a quartz cell 
226 (10 mm optical path length) against a blank of dissolution media. The assay was carried out in 
227 triplicate. 
228
229 2.2.2.10. Biological Activity of loaded and unloaded films
230 2.2.2.10.1. Halo zone test over time
231 Halo zone test was performed following the guidelines of the disc diffusion method 
232 described in CLSI document M44-A2 [36]. C. albicans (ATCC 10231) was cultured in 
233 Sabouraud’s dextrose agar 24 h before testing. Testing was carried out on agar plates (150 
234 mm diameter) containing Mueller-Hinton agar, supplemented with 2% glucose (2 g/100 mL) 
235 and 0.5 μm/mL methylene blue, at a depth of 4.0 mm. The inoculants were prepared by 
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236 suspending five distinct colonies in 5 mL of sterile distilled water and shaking on a vortex 
237 mixer for 15 s. The agar surface was inoculated by dipping sterile cotton swabs into a cell 
238 suspension adjusted to a turbidity of a 0.5 McFarland standard (approximately 1 – 5 x106 
239 CFU/mL) and by streaking the plate surface in three directions. The plate was allowed to dry 
240 for 20 min, then the TCZ powder (0.34 mg), used as control, was placed attached to a Scotch 
241 tape onto the agar surface. Additionally, ovule content (mass equivalent to 0.34 mg TCZ) was 
242 embedded in a paper disc and placed onto the agar surface. Each film, paper disc, and Scotch 
243 tape was moved to another area of the culture after 2, 4, 6, 8, 10, 24, 48, 72, and 96 h (4 days).  
244 After that, the plates were incubated in air at 28°C and read after 24 h. Halo diameters (in 
245 millimeters) for the zone of complete inhibition were determined using a caliper, and the 
246 mean value was recorded (Tejada et al., 2018a).
247
248 2.2.2.10.2. Time-kill
249 C. albicans ATCC 10231 was cultured in Sabouraud dextrose agar (SDA) 24 h before 
250 testing. The inoculum was prepared by suspending five distinct colonies in sterile distilled 
251 water and shaking on a vortex mixer for 15 s. Cell suspension was adjusted to the turbidity of 
252 a 0.5 McFarland standard (approximately 1– 5x106 CFU/mL). TCZ (0.34 mg), ovule (2.38 mg 
253 equivalent to 0.34 mg TCZ) and films (disc with a diameter of 5 mm equivalent to 0.34 mg 
254 TCZ) were placed in 5 mL of inoculum. The suspensions were mixed for 20 s with a vortex 
255 mixer, and samples (0.05 mL) were taken at 0, 30, 60, 90, 120, 150, 180, 210, 240 and 360 
256 min, and serially diluted before spreading onto SDA. The plates were incubated for 24 h and 
257 the viable colonies were evaluated. The time-kill curves (Cantón et al., 2009) were 
258 constructed by plotting the CFU/mL surviving at each time point in the presence and absence 
259 of the formulations. Experiments were conducted in triplicate and the mean number of 
260 survivors was determined. 
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261 2.2.2.11. Cytotoxicity of loaded and unloaded films
262  2.2.2.11.1. Extraction assay from films
263 To achieve the extraction of the film components, discs (5 mm diameter) were placed 
264 in the sidewalls of a 12 well plate and Dulbecco's modified Eagle's medium (DMEN , 1200 
265 L) was added to each well and incubated at 37 ºC for 12-16 h. Then, the media were used for 
266 the analysis of cellular metabolic activity by MTT assay. 
267
268 2.2.2.11.2. Cytotoxicity 
269 Human HCC cell lines Huh7 were obtained from JCRB Cell Bank (Tokyo, Japan). 
270 The top priority of this assay was to measure cell damage by the drugs. The use of different 
271 cell lines other than vaginal-derived cells was considered as a proper system since we did not 
272 mean to measure any hepatic effects; rather, we measured cytotoxicity of the drugs and their 
273 combinations with polymers. Allen et al. reported that cell lines tend to exhibit problems in 
274 stability and/or viability, and because of this, they do not always prove to be the ideal system. 
275 Thus, the use of cell lines able to overcome these limitations, such as those derived from other 
276 tissues, is recommended as a feasible alternative, especially regarding new potential 
277 applications in drug testing therapy (Allen et al., 2005). Cells were maintained in Dulbecco’s 
278 modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU/mL 
279 penicillin, and 100 μg/mL streptomycin at 37 °C in a humidified atmosphere of 95% O2 and 
280 5% CO2. In all experiments, cells were treated after 24 h of attachment with 200 μL extraction 
281 media. Control (untreated) cells were incubated without TCZ.
282 2.2.2.11.3. MTT assay
283 Cells were seeded in 96-well plates at a density of 3500 cells/well. After 24 h of 
284 attachment, cells were treated for 24 h with the different extraction media obtained in section 
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285 2.2.2.10.1. After treatment, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
286 bromide (MTT; Sigma-Aldrich Corp.) was added into the culture medium to assess its 
287 metabolization, as previously described (Ferretti et al., 2016). Absorbance of the metabolite 
288 produced from viable cells was detected at 540 nm (reference filter 650 nm) in a DTX 880 
289 multimode detector (Beckman Coulter Inc., Fullerton, CA, USA). Results were expressed as 
290 percentage of absorbance in control cells. 
291
292  2.2.1.12. Statistical analysis and graphics software
293 Analysis of variance was used, and when the effect of the factors was significant, the 
294 Tukey multiple ranks honestly significant difference test was applied (Origin 8.5, 
295 OriginLabCo., Northampton, USA). Differences at p < 0.01 were considered significant. 
296
297 3. Results and discussion
298 3.1. Mechanical properties
299 Loaded and unloaded films were uniform in texture. The thickness (Figure 1A) was 
300 found to range from 0.197 ± 0.064 to 0.297 ± 0.033 mm, which was significantly smaller than 
301 the ovule (25x10x10 mm). Therefore, the films could produce lesser discomfort after 
302 application than the ovule. It should be mentioned that the thickness of the films was even 
303 smaller than that obtained by Dobaria et al. They developed itraconazole bioadhesive vaginal 
304 films and considered as the optimal formulation a film with a thickness of 0.46 mm (Dobaria 
305 et al., 2009). Folding endurance was performed in order to evaluate film flexibility to produce 
306 a secure application. Prepared films were folded 300 times without breaking, meeting the 
307 folding endurance test (Avachat et al., 2013). The elongation value (Figure 1B) of film S4 
308 (based on CH and 40 % w/w PEG 400) was the highest (p < 0.01). This fact could be 
309 explained by the combination of both high CH concentration and high percentage of 
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310 plasticizer. This result is in agreement with that previously obtained by Suyatma et al. 
311 (Suyatma et al., 2005), where the highest elongation for CH films was obtained when PEG 
312 400 at 40% was used as plasticizer. Also, when comparing formulations S3 and S4, it can be 
313 noted that a high HPMC ratio (0.75) produces a decrease in the elasticity values of the films. 
314 These results are in agreement with those obtained by Tejada et al., indicating a remarkable 
315 reduction in the elongation values of CH films when combined with HPMC at 50% w/w 
316 (Tejada et al., 2017a). It is worth mentioning that high concentrations of plasticizers 
317 combined with CH as a polymer former could increase the elongation value, producing a 
318 decrease in the tensile strength (Domjan et al., 2009); however, load at break values (Figure 
319 1C) ranged from 9 to 11 N with no significant differences among them (p > 0.01). The 
320 characteristics of films, based on biopolymers depend on an equilibrium between the degree 
321 of interactions in the polymeric matrix (which may induce brittleness), and the addition of 
322 plasticizers for better workability. It has been reported that above a critical concentration, the 
323 plasticizer can exceed the compatibility limit with the biopolymer, and phase separation with 
324 plasticizer exclusion is usually observed (Vieira et al., 2011). In this work the combinations of 
325 CH, HPMC, and PEG 400 at the assayed concentrations produced neither brittleness nor 








332 Figure 1. A) Thickness, B) Elongation at break C) Load at break D) Mucoadhesive strength 
333 E) Sweeling index
334
335 3.2. Films swelling and adhesiveness 
336 Figure 1E shows that films based only on CH (S2 and S4) swelled more than CH-
337 HPMC films (S1 and S3), this fact could be related with the pH value of the simulated 
338 vaginal fluid (pH=4.2). At this pH value, CH is protonated (Dey et al., 2018; Wang et al., 
339 2006); thus, the more CH, the more charges, so there is more interaction with simulated 
340 vaginal fluid and more fluid retention. The presence of HPMC in the formulated films did 
341 not improve the swelling process due to the fact that high concentrations of HMPC could 
342 decrease water permeability. Additionally, different results of the swelling process could 
343 be due to the presence of the plastizicer. Conzatti et al. clearly described a CH 
344 formulation film, employing high PEG 400 concentrations as a plastizicer, observing 
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345 PEG-PEG interactions instead of PEG-CH interactions (Conzatti et al., 2018). 
346 Consequently, a more organized, rigid structure was obtained, and thus the swelling could 
347 decrease. This phenomenon is observed in Figure 1E. Formulation S2 presented 
348 maximum swelling values, followed by formulation S4. The presence of high 
349 concentrations of CH improved water uptake, but the inclusion of a high concentration of 
350 plasticizer (40%), generated the opposite effect. A similar analysis was done observing 
351 Figure 1E, samples S3 and S1. Mucoadhesive strength results showed no significant 
352 differences among the formulated films (p > 0.01). Several works reported that as the 
353 swelling index increases the adhesive strength decreases. This fact is attributed to 
354 overhydration of the polymers that led to disentanglement at the polymers/tissue 
355 interface, resulting in an abrupt drop in adhesive strength (Bassi and Kaur, 2015; Peh and 
356 Wong, 1999). Based on the obtained result, the swelling of S2, despite being the highest, 
357 is not enough to decrease the adhesiveness of this formulation in comparison with S1, S3 
358 and S4 (p > 0.01).
359
360 3.3. Spectroscopy data  
361 Figure 2 shows the infrared spectra obtained for TCZ, polymers, plasticizer, commercial 
362 ovule and films. The FTIR-ATR spectrum of TCZ (Figure 2Aa, Table 2) was in agreement 
363 with the reference of the standard TCZ (KBr discs) of BP 2010 (British Pharmacopeia 
364 Comission, 2010). The characteristic peaks corresponding to (C═N) of the imidazol group 
365 1562.3 cm-1, δ(C─H ) 1464.0 cm-1, (C=C) 1433.1 cm-1, (C─N) 1278.8 cm-1, (C─O─C) 
366 1118.7 cm-1, (C─S) 733.0 cm-1 and (C─Cl) 626.9 cm-1 were identified (Bisht et al., 2015; 





370 Figure 2. FTIR-ATR spectra. A) Components of films: a) TCZ, b) CH, c) HPMC d) 
371 PEG 400, B) Films and ovule: e) S1, f) S2, g) S3 h) S4 and i) Ovule.
372
373 The ATR-FTIR spectrum of CH (Figure 2Ab) showed a typical band between 3000-
374 3600 cm-1, concerned with –OH groups, which is broad due to overlapping with the stretching 
375 band of –NH (Pawlak and Mucha, 2003). Other bands were also observed centered at: 2925 
376 cm-1 (stretching vibration of C─H bond); 1643cm-1 (amide I); 1595 cm-1 (NH2 bending) 
377 (Tejada et al., 2017b); 1418 cm-1 (carboxyl –COOH) (Li et al., 2005); 1326 cm−1 (Amide III) 
378 (Kumar et al., 2017); 1150 cm-1  (stretching of the C–O–C bridge); 1060 cm-1 and 1020 cm-1 
379 associated to the C–O stretching vibration (Espinosa-Andrews et al., 2010); and finally the 
380 band at 892 cm-1 assigned to the absorption peaks of β-(1,4) glycosidic unions in CH (Yue et 
381 al., 2009). 
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382 The HPMC spectrum (Figure 2Ac) in the region 3600-3200 cm-1 shows a band 
383 associated with the presence of hydroxyl groups while the band in the region 3000-2800 cm-1 
384 represents the absorptions of C–H vibration modes from methyl group (Ding et al., 2015). 
385 The band arising from –OH bonds on the glucose molecule appears at 1313 cm-1 and the 
386 peaks at 1373 and 1451 cm-1 resulted from C─H bending and stretching modes from methyl 
387 groups (Wang et al., 2007). The most intense peak in the HPMC spectrum occurred at 
388 1050 cm−1 (C─O) and represents out-of-phase vibrations associated with an alkyl substituted 
389 cyclic ring containing ether linkages (Akinosho et al., 2013). The peak centered at 944 cm-1 
390 represents the in-phase vibrations from ether linkages and appeared as a weaker band attached 
391 to the band at 1050 cm-1 (Coates, 2000).
392 The spectrum of plasticizer (Figure 2Ad) PEG 400 presented a very intensive band 
393 around 1100 cm−1 usually assigned in alcohols to either the ν(C–O) stretching or the in-plane 
394 bending (δ) vibration of the C–O–H-group, and in ethers to the stretching ν(C–O–C) 
395 vibration. The stretching ν(C–C) and deformational δ(–CH2–) modes are also active in this 
396 range (Rozenberg et al., 1998). The vibration band at 1300 cm−1  (antisymmetric stretch) 
397 corresponds to the C–O–C ether stretch (Alcantar et al., 2000), while at 1348 cm−1 the (C–O–
398 H) deformational (in-plane) band appears (Rozenberg et al., 1998). The bands peaking at 
399 2960 and 2869 cm−1 correspond to –CH2 stretching vibrations (Alcantar et al., 2000).
400 The films (Figure 2Be-h) showed additional bands corresponding to lactic acid at 1727 
401 cm-1 (C=O group); at 1220 cm-1 (O–H and C–O both from the acid group) and at 1120 cm-1 
402 (C–O alcohol group).
403  Several differences were observed when evaluating the IR spectra of the commercial 
404 form and films (Figure 2B). The ovule (Figure 2Bi) presented only 7 bands, 4 of them may 
405 correspond to TCZ (at 733 cm-1, present in the spectrum as a shoulder; at 1338.6 cm-1; at 
406 1375.3 cm-1and at 1456.5 cm-1). In addition, the spectrum showed two bands comprised 
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407 between 2840 and 2950 cm-1 corresponding to C-H stretches of alkanes due to excipients of 
408 the ovule. The corresponding bands and assignments of the films developed are described in 
409 Table 2.
410
411 Table 2. FTIR-ATR spectroscopic data and assignment of the developed systems.
Wavenumber 
(cm-1) S1 S2 S3 S4 Assignment
627* + TCZ
688 + + TCZ
743 + + Low intensity TCZ
787 + + + TCZ
883 + + PEG
945 HPMC
1120 +* + + Lactic Acid
1220 + + Lactic Acid
1270-1315 + + PEG
1247 + +* PEG
1287 + TCZ
1348 + + + PEG
1727 + + + + Lactic Acid
412 * Signals corresponding to a shoulder
413    
414 3.4. Thermal analysis 
415 DSC curves show that TCZ exhibited a single endothermic peak (Figure 3A) without 
416 shoulders at 82.8 ºC, with an onset temperature of 77.6 ºC associated with the melting process 
417 (Ribeiro et al., 2016). This result is in agreement with the value reported (82 ºC) in the 
418 literature (British Pharmacopeia Comission, 2013). The calculated melting heat was 71.17 J/g 
419 and no re-crystallization peak was observed in the corresponding cooling curve. The 
420 thermogram of the commercial ovule (Figure 3B) shows an endothermic peak centered at 80.4 
421 ºC, corresponding to the melting point of TCZ, which is slightly shifted to the right, probably 
422 due to some interactions with the excipients. Similar shifts were observed in previous works 
423 that studied drug-excipient compatibility. It was reported that these minor changes in the 
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424 melting endothermic peak of drug could be due to the mixing of drug and excipient, which 
425 lowers the purity of each component in the mixture and may not necessarily indicate potential 
426 incompatibility (Abrantes et al., 2016; Charde et al., 2008; Verma and Garg, 2005). On the 
427 other hand, no endothermic peak related with TCZ was observed in DSC analysis of the films 
428 (Figure 3C-F). The absence of the endothermic peak of TCZ could suggest that the drug is in 
429 amorphous state when loaded in the films (Rask et al., 2018; Senta-Loys et al., 2017).
430
431
432 Figure 3. DSC thermograms. A) TCZ B) Ovule and C-F) films (S1, S2, S3, S4 respectively). 
433
434 Regarding TGA (Table 4) and DTGA analysis, the commercial ovule exhibited 2 stages 
435 of degradation (Figure 4A), unlike TCZ whose degradation takes place in one stage (max 
436 peak 297.8 ºC Figure 4A). The greatest loss of mass (92.24%) in the decomposition of the 
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437 ovule took place between 30 and 360 ºC, with two maximum peaks of decomposition at 304.8 
438 (related to TCZ) and 321.3 ºC (related to excipients). 
439
440
441 Figure 4. TGA and DTGA curves. A-B) TCZ and Ovule C-D) CH, HPMC, B2, B1, PEG 400 
442 E-F) films S1, S2, S3, S4 and TCZ.
443
444 Figures 4C and 4D show that both polymers (HPMC and CH) in solid state showed 2 
445 main degradation peaks, the first thermal event occurs in the temperature range 30-100 ºC and 
446 is attributed to the evaporation of water (de Britto and Campana-Filho, 2004). The second one 
447 occurs in the temperature range 200-400 ºC, and it is attributed to the thermal degradation of 
448 each polymer (345.9 ºC for HPMC/ 289.6 ºC for CH respectively) (de Britto and Campana-
449 Filho, 2004; Li et al., 1999). 
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450 Films B1 and B2 containing only the polymers showed some differences with respect to 
451 solid polymers (Figures 4C and 4D). In the case of B1, 4 peaks can be observed; the first at 
452 59.1 ºC is due to free water; the second, centered at 191.9 °C could be associated with water 
453 retained by polar interactions (Lavorgna et al., 2010); the next one, centered at 311.6 °C, 
454 corresponds to the fusion of CH (de Britto and Campana-Filho, 2004) and the last one, 
455 centered at 349.1 °C, corresponds to the fusion of HPMC (Li et al., 1999). B2 exhibited 3 
456 peaks; one centered at 94.1 ° C associated to water linked through hydrogen bonds; another 
457 one at 179.5 ° C, which is related to water retained by polar interactions and finally the peak 
458 at 281.1 ° C, which is associated to the degradation of the polymer (Cardenas and Miranda, 
459 2004).
460 The DTGA curve of the plasticizer exhibited three peaks (Figure 4 D); the first one 
461 centered at 81.2 ° C, is related to water linked through hydrogen bonds whereas the other two 
462 peaks, at 326.1 ° C and 362.7 ° C, correspond to the pyrolysis of PEG groups (Sadeghpour et al., 
463 2018; Zhang et al., 2013). 
464 The decomposition stages of the films can be observed in Figure 4E and 4F (Table 3). 
465 Whereas 3 stages are displayed for films based on CH, 4 stages were observed for films based 
466 on both polymers. For films S1 and S3, the first 2 peaks (52.7 and 171.1 ºC for S1 and 56.8 
467 and 176.4 ºC for S3) have the same meaning as for B2, i.e. water volatilization; the third 
468 could be associated to simultaneous degradation of the drug and the CH (268.8 ºC for S1 and 
469 289.2 ºC for S3), and the fourth peak is attributed to HPLC (353.5 and 353.1 ºC). S2 and S4 
470 films exhibit only the first 3 peaks (Figure 4F) because these films do not contain HPMC in 
471 their composition. On the other hand, a decrease in the remaining mass was registered when 























Ovule - 30-360 304.8/321.3 360-550
S1 9,98 25-100 52.70 100-215 171.02 215-304 268.78 304-425 353.54
S2 25,95 25-133 90.31 133-234 186.31 234-478 281.25
S3 8,62 25-105 56.80 100-224 176.45 224-310 289.20 310-433 353.03
S4 16,06 25-123 81.57 123-240 185.95 240-478 292.39
476
477 3.5.  XRD analysis 
478 The crystalline character of the drug was analyzed through an XRD analysis (Figure 5). 
479 The TCZ raw material (Figure 5A) showed an intense peak at 22.33 º, which was mentioned 
480 in a previous report (Ribeiro et al., 2016). Also, diffraction peaks at 2θ around 8.71 º; 10.39 º; 
481 13.49 º; 13.67 º; 13.83 º; 16.35 º; 17.45 º; 17.93 º; 18.71 º; 20.33 º; 20.69 º; 24.01 º; 24.61 º; 
482 25.33 º; 25.67 º; 26.27 º; 27.31 º; 27.53 º; 28.39 º; 28.99 º; 29.39 º; 29.83 º; 31.47 º; 32.17 º; 
483 32.77 º; 33.13 º 36.95 º and 38.59 º were observed. The ovule (Figure 5B) showed 8 peaks 
484 corresponding to the TCZ at 22.33 º, 27.31 º, 27.53 º, 28.39 º, 29.83 º, 31.47 º, 32.17 º and 
485 33.13 º. Probably, the reduction in the intensities of the peaks regarding TCZ raw material is 
486 due to the excipient dilution effect. On the other hand, no peaks were observed when 
487 analyzing the spectra of the films (Figure 5 C-F), which is in agreement with the results 
488 obtained by DSC, confirming the hypothesis that TCZ is in amorphous state inside the films 





492 Figure 5. XRD pattern. A) TCZ B) Ovule C) S1 D) S2 E) S3 F) S4
493
494 3.6. SEM analysis 
495 Morphology of films was analyzed by SEM (Figure 6). Figure 6A-D shows the SEM 
496 images of the surface and cross-sectional fracture of the films studied. The morphology of the 
497 films shows that all formulations were symmetric and uniformly distributed. In superficial 
498 section, film S1 based on CH-HPMC with 5% w/w PEG 400 (Figure 6A-A2) presented a 
499 homogeneous and smooth surface even at 5000x magnification, while film S3 based on CH-
500 HPMC with 40% w/w PEG 400 presented a few signs of roughness at 5000x (Figure 6C2) 
501 which may be attributed to the increase in the plasticizer content. On the other hand, films 
502 based only on CH (S2 and S4) showed to be porous and presented roughness at higher 
503 magnifications (Figure 6B3 and D3), which could be related to the interaction between CH and 
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504 the plasticizer during the drying process (Al-Hassan and Norziah, 2012). As observed, the 
505 roughness increased in films containing 40% w/w PEG 400 (Figure 6C2 and D2).
506
507
508 Figure 6. Scanning electron microscopy. A) S1 B) S2 (C) S3 (D) S4. Micrographs with 
509 different magnifications and orientation. Surface: A-D) 200x A1-D1) 1000x A2-D2) 5000x and 
510 film transversal section B3-D3)1000x.
511
512 It is important to remark that films based on CH and HPMC (Figure 6A and 6C) 
513 presented a dense and compact structure, suggesting high structural integrity and good 





517 3.7. Dissolution Studies
518 Figure 7 shows the dissolution profiles of TCZ raw material and films. The films 
519 showed fast drug release, reaching almost 100% after 60 min (Figure 7). At 30 min assay, 
520 only 3.9 % of TCZ raw material was released (Q30=3.9 %), while the films allowed a 
521 significant improvement in TCZ dissolution rate (S1 Q30 = 96.0 %, S2 Q30 = 88.2 %, S3 Q30= 
522 97.5 %, and S4 Q30=83.5 %). The result is probably due to the fact that TZC modified its solid 
523 state when loaded in the films, as observed in DSC and XRD analysis. On the other hand, 
524 TCZ raw material presented incomplete dissolution after 360 min assay (Q360=14.6 %). This 
525 poor dissolution is related to the TCZ structure, which is highly hydrophobic, belonging in 
526 class II in the Biopharmaceutical classification system (BCS) (Kasim et al., 2004). 
527 This assay is useful for the analysis of TCZ release from the films; however, the assay 
528 conditions are not representative of the vaginal cavity, which presents humidity instead of 900 
529 mL of fluid. To study TCZ release as well as its activity over time in a humid medium, the 
530 “halo zone test over time” was carried out. 
531




534 3.8. Biological activity
535 3.8.1. Halo zone test over time
536 Halo zone test over time was performed in order to analyze both the release of TCZ and 
537 the activity of different formulations over time when exposed to a humid zone. Figure 8 
538 shows the different halos produced over time by TZC raw material (added to a Scotch tape 
539 disc), ovule content (embedded in a disc of absorbent paper), different film formulations, and 
540 empty films (B1 and B2). As observed B2 based on 100% CH showed activity for 48 h, while 
541 no inhibition halo was observed when B1 (based on CH:HPMC) was assayed. The ovule 
542 presented antifungal activity until the end of the assay (5 mm). Films loaded with TZC 
543 showed greater activity than both the ovule and TCZ raw material, producing inhibition halos 
544 between 26-34 mm of diameters after 96 h assay. After 96 h, the percentage of reduction in 
545 the diameter of the halo for the ovule in comparison with the first determination (2 h) was 
546 89%, while the films showed reductions between 24 and 41% (S1= 35 % S2= 24 % S3= 38 % 
547 S4= 41 %), suggesting a more time-sustained release of TCZ for the films.
548 No differences were observed between the behavior of the S3 and S4 formulations at the 
549 end of the assay. On the other hand, S2 film (based on 100% CH and 5% PEG 400) produced 
550 the highest inhibition halo at 24, 48, 72, and 96 h (p < 0.01); this result could be related with 
551 both the swelling (Figure 1E) of the formulation (related with the highest release of TCZ from 




554 Figure 8. Halo zone produced by TCZ, films (S1-S4 and B2) and the commercial ovule.
555
556 3.8.2. Time-kill
557 Time-kill studies were performed to assess the exposure time required to kill a 
558 standardized Candida inoculum. Plots of TCZ activity were built as CFU/mL versus time 
559 (Figure 9). Times to obtain 99.9% reduction in the number of CFU/mL were different for each 
560 formulation. It was observed that the control curve did not show any decrease in the number 
561 of colony forming units compared with the initial inoculums, while a reduction in CFU was 
562 observed even when unloaded film only containing CH was assayed. It has been reported that 
563 low concentrations of CH produce a series of alterations of ion homeostasis and metabolism 
564 of the yeast while at high concentrations it may act as a permeation agent for bacteria and 
565 fungi (Peña et al., 2013). Thus, when CH is used at concentrations higher than 1.0 mg/mL, not 
566 only a fungistatic but also a fungicidal activity is observed. In this assay the CH concentration 
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567 (when placing unloaded film based only on CH into the medium) was higher than 1.0 mg/mL, 
568 therefore, this unloaded film (B2) presented fungicidal activity itself. On the other hand, when 
569 CH was used at 25% (B1) the concentration in the medium was lower than 1.0 mg/mL and no 
570 decrease in the number of colony forming units compared with the initial inoculums was 
571 observed.
572
573 Figure 9. CFU/mL surviving at each time point in the presence and absence of the different 
574 formulations.  
575
576 When TCZ was loaded, the activity of the formulations was directly related to the drug, 
577 and just small differences between time-kill curves of loaded films (S1-S4) were found 
578 (Figure 9).  The fastest activity was obtained when loaded CH (15 minutes) or CH-HPMC (30 
579 minutes) based films were assayed; on the other hand, both TCZ raw material and the ovule 
580 needed 360 minutes to reach this reduction. This was probably related to the higher and faster 
581 dissolution of TCZ when it is loaded in the films (Figure 7), which may improve its diffusion 
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582 in the agar medium. This increase in TCZ diffusion may explain the higher activity of the 
583 films with respect to TCZ pure drug and ovule. 
584
585 3.9. Cytotoxicity of loaded and unloaded films
586 Regarding cytotoxicity (Figure 10), films only based on CH induced a 35 to 54 % reduction in 
587 cell viability after 24 h incubation, as compared to control films. It has been reported that CH 
588 seems to be cytostatic towards fibroblasts; due to the fact that it inhibits cell proliferation. 
589 Thus, CH-based materials would alter cell growth; however, Shahabeddin et. al found that 
590 combinations of CH with other materials, such as collagen and glycosaminoglycans, allow 
591 improvement of its cytocompatibility (Shahabeddin et al., 1991). On the other hand, films 
592 based on CH-HPMC (loaded and unloaded) did not produce any cytotoxicity effects. 
593
594





598 In this work, vaginal films based on CH alone and combined with HPMC using different 
599 contents of PEG as plasticizer were successfully developed and characterized as an alternative 
600 dosage form for the treatment of vaginal candidiasis. Formulated films showed similar 
601 mechanical properties and adhesiveness. The films were able to swell for 24 h without 
602 suffering disintegration; however, films based only on CH showed the highest swelling and, 
603 therefore, may produce discomfort after application. The developed films displayed faster 
604 activity against Candida albicans than both TCZ pure drug and TCZ ovule, which is probably 
605 associated with the fact that TCZ is inside the films in amorphous state. Additionally, films 
606 presented controlled release of TCZ, showing strong antifungal activity after 96 h assay. 
607 Those formulations based only on CH presented a certain degree of cytotoxicity and, 
608 therefore, their use should be avoided. The system based on CH-HPMC with 40% PEG 400 
609 as plasticizer showed fast and sustained antimicrobial activity and also the lowest swelling 
610 value. Additionally, this formulation produced no cytotoxic effects, showing that this film is a 
611 promising alternative dosage form for the treatment of vaginal candidiasis. All these tests 
612 should be supplemented by in vivo tests in the near future.
613
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